PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer

PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer

Pharmacologic inhibition of PARP is the primary therapeutic strategy for BRCA mutant ovarian cancer. However, most of patients carry wild-type BRCA1/2 with no significant clinical benefits from PARP inhibitors, calling for the needs to further understanding and developing new strategy when employing...

Full description

Bibliographic Details
Main Authors: Ting Hong, Guang Lei, Xue Chen, He Li, Xiaoye Zhang, Nayiyuan Wu, Yu Zhao, Yilei Zhang, Jing Wang
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Redox Biology
Subjects:
PARP
Ferroptosis
Lipid peroxidation
SLC7A11
Ovarian cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2213231721000768

Internet

http://www.sciencedirect.com/science/article/pii/S2213231721000768

Similar Items